PHARMACEUTICALS face competitive hurdles from numerous sources: the scientific risk in innovation is not trivial; then there is the Regulatory risk, where good drugs fail not because they are bad but due to trial design or lack of statistical power in a study; and finally, even when these two immense hurdles are overcome, agencies like Britain’s NICE, or the US equivalent give the thumbs up or down on actually paying for the medicine.
http://lnkd.in/2j4hWn
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022